Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIA 5-1058 first-in-human single and multiple ascending dose study in healthy male volunteers
NL-OMON36800Phase 1Active, not recruiting
- Sponsor
- BIAL
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zamicastat in hypertension (HTN) and chronic heart failure (CHF) (5 arms), sponsored by BIAL. Primary endpoints: Safety and tolerability, Plasma pharmacokinetics and 4 more. Started Mar 2011; status: active, not recruiting.
02
Drugs
zamicastat
03
Conditions
hypertension (HTN)chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON36800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36800.